XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.2
Supplemental Financial Information (Tables)
6 Months Ended
Jun. 30, 2025
Other Balance Sheet Details [Abstract]  
Schedule of Inventories
Inventory consisted of the following:
(in millions)June 30,
2025
December 31,
2024
Raw materials$28.0 $33.7 
Work in process15.5 10.9 
Finished goods13.6 12.8 
57.1 57.4 
Less inventory reserves
(0.2)— 
Total inventory
$56.9 $57.4 
Schedule of Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consisted of the following:
(in millions)June 30,
2025
December 31,
2024
Sales rebates and reserves$175.6 $144.2 
Accrued employee related costs84.6 107.5 
Accrued development costs (including unpaid development milestones)
61.0 50.8 
Current branded prescription drug fee38.0 49.2 
Current income taxes payable
25.7 9.9 
Accounts payable and other accrued liabilities104.6 100.0 
Total accounts payable and accrued liabilities$489.5 $461.6 
Schedule of Other Noncurrent Liabilities
Other noncurrent liabilities consisted of the following:
(in millions)June 30,
2025
December 31,
2024
Noncurrent income taxes payable
$183.0 $160.7 
Other noncurrent liabilities
27.1 5.5 
Total other noncurrent liabilities$210.1 $166.2 
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.
(in millions)June 30,
2025
June 30,
2024
Cash and cash equivalents$264.0 $139.7 
Restricted cash included in other noncurrent assets
8.0 8.0 
Total cash, cash equivalents, and restricted cash$272.0 $147.7